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ABSTRACT
Objective: Tumor registries in integrated healthcare systems (IHCS) have high precision for identifying incident
cancer but often miss recently diagnosed cancers or those diagnosed outside of the IHCS. We developed an
algorithm using the electronic medical record (EMR) to identify people with a history of cancer not captured in
the tumor registry to identify adults, aged 40–65 years, with no history of cancer.
Materials and Methods: The algorithm was developed at Kaiser Permanente Colorado, and then applied to
7 other IHCS. We included tumor registry data, diagnosis and procedure codes, chemotherapy files, oncology
encounters, and revenue data to develop the algorithm. Each IHCS adapted the algorithm to their EMR data and
calculated sensitivity and specificity to evaluate the algorithm’s performance after iterative chart review.
Results: We included data from over 1.26 million eligible people across 8 IHCS; 55 601 (4.4%) were in a tumor
registry, and 44848 (3.5%) had a reported cancer not captured in a registry. The common attributes of the final
algorithm at each site were diagnosis and procedure codes. The sensitivity of the algorithm at each IHCS was
90.65%–100%, and the specificity was 87.91%–100%.
Discussion: Relying only on tumor registry data would miss nearly half of the identified cancers. Our algorithm
was robust and required only minor modifications to adapt to other EMR systems.
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Conclusion: This algorithm can identify cancer cases regardless of when the diagnosis occurred and may be
useful for a variety of research applications or quality improvement projects around cancer care.

INTRODUCTION
Longitudinal cohort studies have been used for decades to understand the etiology of chronic disease and have made important contributions to public health.1–4 Many cohort studies have drawn
from specific populations, such as teachers,5,6 agricultural workers,7
or healthcare providers8–10 and are designed to study a wide range
of outcomes. Currently, the All of Us research program is assembling a cohort across the United States designed to study a variety of
disease outcomes.11 Similar to other cohorts built with a specific disease endpoint in mind, such as the Framingham Heart Study and the
Cancer Prevention Studies,3,4,12,13 we are developing a new prospective cohort, Connect for Cancer Prevention Study (https://dceg.cancer.gov/research/who-we-study/cohorts/connect).
In collaboration with the National Cancer Institute, Connect
aims to inform new approaches in precision prevention and early detection of cancer.14 This prospective cohort will incorporate recent
developments in digital technologies, biomarkers, and exposure
assessments to advance the study of suspected and emerging factors
that influence cancer development, treatment, and survival. The cohort aims to enroll 200 000 adults aged 40–65 years who are members or patients of a participating integrated healthcare systems
(IHCS) across the United States with no personal history of invasive
cancer.
Tumor registries are considered the “gold standard” for identifying incident cancer within a population.15–18 However, they usually
do not include recently diagnosed cases, as fully annotated data can
lag up to 2 years. Further, IHCS tumor registries usually do not
track cases diagnosed and/or treated outside of the health system.
Utilizing both tumor registries and large electronic medical record
(EMR) databases can provide a more complete capture of all cancer
cases, regardless of when or where they were diagnosed. Previously,
we presented an algorithm that was developed to identify a history
of cancer within a single IHCS.19 This original algorithm was developed and tested within Kaiser Permanente Colorado (KPCO) and
contained 2013 administrative data utilizing diagnosis codes, chemotherapy treatment codes, oncology encounters, and the KPCO tumor registry to identify a member’s history of cancer. Our current
works build off the Clarke and Feigelson publication through external validation of the algorithm at multiple IHCS and use more
updated diagnosis, treatment, and procedures codes. We aimed to
develop an algorithm with a high specificity that leverages both our
EMR systems and our local tumor registries to identify cancer-free
adults who are eligible to participate in Connect. We then adapted
and tested the algorithm for use at 7 other IHCS.

MATERIALS AND METHODS
Setting
The algorithm was developed at KPCO; 7 other IHCS adapted and
validated the algorithm. Each organization maintains an Epic-based
EMR for each health plan member and/or patients aligned with primary care and specialty providers. KPCO serves approximately 550
000 members in the greater Denver metropolitan area. Kaiser Permanente Georgia (KPGA) has clinics located around the Atlanta,

Georgia metropolitan and Northern Georgia area with over 300 000
members. Kaiser Permanente Hawaii (KPHI) serves the entire state of
Hawaii including more than 250 000 members with facilities on
4 islands. Kaiser Permanente Northwest (KPNW) provides medical
coverage for over 600 000 members in northwest Oregon and southwest Washington. HealthPartners (HP) Institute is the largest
consumer-governed nonprofit healthcare organization in the United
States, serving more than 1.8 million medical and dental health plan
members nationwide; more than 1.2 million of these patients are in
Minnesota and western Wisconsin. Henry Ford Health System
(HFHS) serves southeast Michigan including Detroit with over 450
000 aligned patients and/or health plan members. University of Chicago is an academic medical center located in Hyde Park on the
South Side of Chicago that serves approximately 375 000 patients.
Sanford Health is a nonprofit health system located in the upper
Midwest serving over 2 million patients across a 250 000 square
mile rural catchment area spanning South Dakota, North Dakota,
and western Minnesota.
The EMR systems maintained at each site contain information on
diagnoses, medical procedures including biopsies, laboratory and imaging tests, pharmaceutical orders, and clinical encounters and encounter types. The robust information available in the EMR enables
each site to identify cancer diagnostic codes, blood or radiology
orders, chemotherapy treatment sessions, and oncology department
visits.20–22 KPCO’s EMR was established in 1998 and includes tumor
registry data beginning in 2000. The EMRs from the other participating 7 IHCS were established between 1996 and 2006 with tumor registries created between 1974 and 2010. This project was reviewed
and approved by the Institutional Review Board at each participating
IHCS, and the requirement for informed consent was waived.

Algorithm initial development
The algorithm was adapted at KPCO from an earlier version based
on International Classification of Diseases Ninth Edition (ICD-9)
codes,19 updated to include contemporary codes and to match
the criteria for the new cohort. Specifically, we included ICD-9 and
International Classification of Diseases Tenth Edition (ICD-10), as
well as International Classification of Diseases for Oncology Third
Edition (ICD-O-3) coding, and attempted to identify both in situ
(stage 0) and invasive disease (stages I–IV). Most invasive cancer diagnoses are included in tumor registries which follow the standards
set forth by the North American Association of Central Cancer Registries (NAACCR);23 however, most in situ cases, with the exception
of in situ breast cancers, are not routinely recorded. Nonmelanoma
skin cancers are not considered reportable cancers and thus, not included in tumor registries.
To develop and test the algorithm, KPCO used 2016 data to ensure the tumor registry, ‘gold standard’ data were complete at each
IHCS participating in this study. The algorithm matched the Connect for Cancer Prevention Study eligibility criteria and identified all
KPCO members aged 40–65 years, and flagged invasive cancers using EMR and tumor registry records with an invasive cancer behavior code. Records with a behavior code identifying in situ disease,
and nonmelanoma skin cancers, were not flagged as having a history
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Chart review
The developed algorithm is intended to go beyond the tumor registry’s data and account for limitations in the tumor registry which
may include cancer cases that were (1) not reportable cases because
they were stage 0; (2) recently diagnosed and not yet captured in the
tumor registry; or (3) diagnosed outside the health plan or prior to
health plan membership. Chart review was specific to records not
reported in the tumor registry. To ensure the algorithm was accurately identifying members without cancer, we selected a random
sample of 100 members not in the tumor registry according to the
following stratification parameters: (a) cancer status as identified by
the algorithm (1:4 cancer vs not cancer; 20 flagged with cancer vs
80 flagged as cancer-free) and (b) age group (1:2 age 40–55 years vs
>55 years) because cancer is more common in older adults. Age
group stratification was applied in each cancer status subgroup,
such that 14 of 20 members the algorithm flagged as having cancer
were over age 55. Chart review was performed on each individual to
indicate an ever diagnosis of cancer before or during 2016.
For internal validation, we tested the algorithm on 100 chart review cases at KPCO. Each chart was fully reviewed by trained research staff to find any documentation of cancer, or to confirm there
was no history of cancer using all notes in the chart dating back to
the patient’s first enrollment, or to the beginning of the EMR
(1998). For the 20 patients, the algorithm identified as having a history of cancer, the abstractor reviewed the EMR at the exact date of
diagnosis; if a diagnosis for cancer was not found, the reviewer then
examined the chart from the administrative diagnosis date in the
EMR going forward in time for a mention of cancer. For the 80
patients, the algorithm identified as not having a history of cancer,
the abstractor examined the patient’s full EMR dating back to the
first enrollment through 2016. The algorithm’s performance was
based on a goal to achieve 80% sensitivity and 80% specificity
to detect any cancer.24 Using chart review batches of 25, we iteratively reviewed the errors revealed by the chart review to modify the
algorithm until the desired sensitivity and specificity were achieved.
When the algorithm identified a patient as having cancer and chart
abstraction found no cancer (false positive) or the algorithm flagged
a patient as cancer-free and chart abstraction reported a history of
cancer (false negative), the IHCS study team met to determine any
pattern to the false positives or negatives that could be improved
upon. After each iteration, a new chart review sample was selected,
as described above, and sensitivity and specificity were recalculated.

External validation
After the desired sensitivity and specificity were achieved at KPCO,
the algorithm was disseminated to the remaining 7 participating
IHCS. To aid in external validation, KPCO developed and refined a
chart abstraction guide that was disseminated to each IHCS. Each
IHCS modified the algorithm to fit their IHCS’ EMR and began
chart review as described above. While it was recommended that
each IHCS complete a minimum of 100 chart reviews to test their algorithm, each site determined how many chart reviews to complete.
KPGA, KPHI, and KPNW maintained the KPCO-developed chart
abstraction and completed 100 chart reviews in 25-batch iterations.
KPNW completed 99 chart reviews, instead of 100, due to discovering 1 member randomly selected for chart review was deceased.
Three sites slightly modified the procedures to better match their
data collection and EMR system. HP used 2020 data and included
all patients age 40–65 years that completed at least 1 primary care
office visit or at least 1 telehealth visit in internal medicine, family
practice, or obstetrics in the past 5 years at a HP-owned facility and
excluded those already in the tumor registry. HFHS utilized the
Health Care System Research Network Virtual Data Warehouse25
2013–2016 to identify 100 cases for chart review. Sanford Health
was unable to pull their total eligible population and did not rely on
a tumor registry; however, Sanford completed 188 chart reviews
from a 2020 sample of 66 390 based on a sample size calculation
with a 2% margin of error. University of Chicago’s Center for Informatics Clinical Research Data Warehouse used 2020 data to modify
the algorithm and identify 100 cases to review. The participating
IHCS completed their chart review and modified the algorithm, as
needed, to achieve the sensitivity and specificity goals.

Statistical analysis
Patient-level descriptive statistics were stratified based on inclusion
in the tumor registry, identification of a history of cancer by the algorithm, or cancer-free. For HFHS, KPCO, KPGA, KPHI, and
KPNW, we calculated the sensitivity and specificity of the final algorithm using the tumor registry, for each region. For these 5 IHCS,
the overall sensitivity to detect cancer is a weighted average of the
sensitivities, where the weight of each subgroup (patients in the tumor registry vs patients not in the tumor registry) is the proportion
of all cancer cases in that subgroup. Figure 1 describes the components and calculation of the weighted sensitivity (H).
The remaining IHCS calculated the sensitivity of the algorithm
based solely on their chart review results, Table 1 box (G).
Specificity was not affected by the distribution of cases and was
calculated for all IHCS as:
True Negatives : No: of cancer  free cases identified by algorithm and chart review
:
Total Negatives from chart review

RESULTS
Table 1 provides a description of the study population for each participating IHCS. Except for Sanford Health for reasons mentioned
in the Materials and methods section, there was a total of 1 265 076
members (HP ¼ 472 714; HFHS ¼ 170 283; KPCO ¼ 173 197;
KPGA ¼ 104 633; KPHI ¼ 76 910; KPNW ¼ 170 181; University of
Chicago ¼ 97 158), with 54.4% female and 45.6% male included
across the IHCS’s algorithm development (Table 1). Cancer-free
individuals were 46.3% male, 63.5% White, and 5.7% Hispanic.
University of Chicago had 9.2% of eligible members with a record
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of cancer, per the eligibility criteria. The developed algorithm initially
flagged any record with an inpatient or outpatient claim with an ICD9, ICD-10, or ICD-O-3 code indicating cancer. The algorithm included the following codes for incident cancer cases, ICD-9: 140-209;
ICD-10: C00-C97; and the following codes for the history of cancer
cases, ICD-9: V10 and ICD-10: Z85. The algorithm excluded ICD-9:
173, 209.4, 209.5, 209.6, V10.83, or V13.89; ICD-10: C44, Z85.828
or Z85.821. ICD-O-3 procedural codes were also included: C000–
C999 with a behavior code of 3 or greater except C440–C449 with
histology codes of 8051–8098. The algorithm also flagged any record
with at least 3 visits in the oncology department on separate days, or
at least 2 records of receiving a chemotherapeutic drug on separate
days (see a complete list of codes in Supplementary Table S1). The
developed algorithm was then tested using manual chart review and
revised based on the chart review findings until the algorithm met
the stated goals. SAS version 9.4 (SAS Institute, Cary, NC, USA)
was used to develop and disseminate the algorithm.
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Table 1. Aggregated characteristics among the integrated healthcare systems participating in the project to develop and modify an algorithm to identify a history of cancer
Total eligible
population
N (%)
Integrated Healthcare Systema
HealthPartners Instituteb
Henry Ford Health Systems
Kaiser Permanente Colorado
Kaiser Permanente Georgia
Kaiser Permanente Hawaii
Kaiser Permanente Northwest
University of Chicago
Sanford Healthc
Patient demographics
Age group
40–44
45–49
50–54
55–59
60–65
Sex
Male
Female
Other
Unknown
Race
Asian
Black
Hawaiian/Pacific Islander
American Indian/Alaska Native
Multiple Race
Other
Unknown
White
Ethnicity
Hispanic
Non-Hispanic
Unknown

No indication of cancer via tumor
registry or cancer algorithm
N (%)

Cancer identified
by tumor registry
N (%)

Cancer identified by algorithm,
not in tumor registry
N (%)

1 164 627 (92.14)
442 618 (93.6)
157 818 (92.7)
161 185 (93.1)
96 960 (92.7)
70 188 (91.3)
150 923 (88.7)
84 935 (87.4)
–

55 601 (4.40)
17 072 (3.6)
7223 (4.2)
5650 (3.3)
3331 (3.2)
4502 (5.9)
8846 (5.2)
8977 (9.2)
–

44 848 (3.55)
13 024 (2.8)
5242 (3.1)
6362 (3.67)
4342 (4.15)
2220 (2.89)
10 412 (6.12)
3246 (3.38)
–

251 083 (19.8)
234 764 (18.6)
245 322 (19.4)
258 404 (20.4)
275 503 (21.8)

243 037 (20.9)
223 179 (19.2)
227 900 (19.6)
233 357 (20.0)
237 154 (20.4)

3812 (6.9)
5909 (10.6)
9359 (16.8)
14 105 (25.4)
22 407 (40.3)

4149 (9.3)
5639 (12.6)
8053 (18.0)
10 955 (24.4)
16 052 (35.8)

576 824 (45.6)
687 955 (54.4)
–
297 (0.02)

539 568 (46.3)
624 768 (53.6)
–
288 (0.02)

21 413 (38.5)
34 183 (61.5)
–
5 (0.01)

15 691 (35.0)
29 155 (65.0)
–
2 (0.00)

81 826 (6.5)
183 693 (14.5)
10 405 (0.8)
4451 (0.4)
20 411 (1.6)
38 425 (3.0)
112 380 (8.9)
813 394 (64.3)

77 286 (6.6)
170 847 (14.7)
9761 (0.8)
4239 (0.4)
27 763 (2.4)
36 667 (3.1)
108 276 (9.3)
739 788 (63.5)

2946 (5.3)
8279 (14.9)
416 (0.7)
149 (0.3)
1844 (3.3)
888 (1.6)
1640 (2.9)
39 439 (70.9)

1600 (3.6)
4581 (10.2)
229 (0.5)
157 (0.4)
801 (1.8)
747 (1.7)
2382 (5.3)
34 351 (76.6)

74 812 (5.9)
846 108 (66.9)
344 156 (27.2)

66 266 (5.7)
768 228 (66.0)
326 166 (28.0)

2558 (4.6)
47 725 (85.8)
5340 (9.6)

6181 (13.8)
30 358 (67.7)
12 456 (27.8)

1 265 076
472 714
170 283
173 197
104 633
76 910
170 181
97 158
–

Note: The table reports the 2016 aggregated data from the participating integrated healthcare systems, with 2 exceptions noted below.
a
Percentiles reported across integrated healthcare systems (IHCS) are based on the IHCS’ total population to report the percent of cancer and cancer-free adults
used in the algorithm development. Percentiles in the remaining table describe the characteristics within each classification.
b
HealthPartners Institute used 2020 data instead of 2016 to modify the KPCO algorithm, as described in the Materials and methods section.
c
Sanford Health was unable to report on the total eligible population and cases within their tumor registry based on the methodology used to modify the
KPCO algorithm.
d
The study included aggregated electronic medical record (EMR) data from 7 integrated healthcare institutions. HealthPartners Institute’s EMR was established in
2000 and includes a tumor registry created in 1984. Henry Ford Health System’s EMR was established in 2013 and includes a tumor registry created in 1985. Kaiser
Permanente Colorado’s EMR was established in 1998 and includes tumor registry data beginning in 2000. Kaiser Permanente Georgia’s EMR was established in
1996 and includes a tumor registry created in 2010. Kaiser Permanente Hawaii’s EMR was established in 2004 and includes a tumor registry established in the
1980s and converted to an electronic database in 2003. Kaiser Permanente Northwest’s EMR was established in 1996 and includes a tumor registry created in 1974.
University of Chicago EMR was established in 2006 and includes a tumor registry created in 1954. Sanford Health’s EMR was established in 2005 and includes a tumor registry created in: Aberdeen, SD (2015), Bemidji, MN (2011), Fargo, ND (2004), Sioux Falls, SD (1983), Worthington, MN (2015), and Bismarck, ND (2002).
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Figure 1. Formula description of the weighted sensitivities calculated for HFHS, KPCO, KPGA, KPHI, and KPNW to account for cancer cases identified in either the
tumor registry or by the algorithm.
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Table 2. Final algorithm attributes across each of the participating integrated healthcare systems
Integrated healthcare systems specific algorithm final version attributes

Tumor registry record
Diagnosis codes
ICD-9
ICD-10
Encounters
Oncology department visit
Chemotherapy treatment
Chemotherapy ICD-9
Chemotherapy ICD-10
Revenue Codes
Current Procedural
Terminology-4
Healthcare Common
Procedure Coding System

X

X

X

X

X

X

X
X

X
X

X
X

X
X

X
X

X
X

X
X

X
X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X
X
X
X

X

X

X

X

X

X

Table 3. Example of calculating KPCO’s weighted sensitivity to account for cancer cases identified in either the tumor registry or by the algorithm
Among eligible population

Percent of cancer cases

Sensitivity

A ¼ 5650
Number of cancer cases
identified in tumor registry
B ¼ 6632

47.04% 5 5650/12 012
D ¼ A/C

F ¼ 100%
Tumor registry sensitivity

52.96% 5 6632/12 012

Number of cancer cases
identified by algorithm

E ¼ B/C

82.35% 5 (14 true positives)/
(17 total cancer cases identified by chart review)
G¼
(Number of true positives from chart review)/
(Number of all cancer cases identified by chart review)
90.65% ¼ (47.04%  100%) þ (52.96%  82.35%)
H ¼ (D  F) þ (E  G)
Weighted sensitivity

12 012 ¼ 5650 þ 6632
C¼AþB
Total number of cancer cases
identified in tumor registry
or by algorithm

The bold text represents the chart review results from KP CO to provide an example of weighted sensitivity calculation.

in their tumor registry, followed by KPHI (5.9%), KPNW (5.2%),
HFHS (4.2%), HP (3.6%), KPCO (3.3%), and KPGA (3.2%).
Among individuals with a reported cancer not captured in the tumor registry, 35.8% were aged 60–65, 65.0% were female, 3.6%
Asian, 10.2% Black, 0.5% Hawaiian/Pacific Islander, 76.6%
White, and 13.8% Hispanic. Compared to cases identified in the
tumor registry, cancer cases identified by the algorithm not in the
tumor registry had a higher percentage of people age 40–44 years
(6.9% vs 9.3%) and 45–49 years (10.6% vs 12.6), more females
(61.5% vs 65.0%), and a higher percentage of Hispanic members
(4.6% vs 13.8%).
Each site revised the algorithm distributed by KPCO through
systematic chart review standardized across IHCS. Table 2 displays the attributes in the final algorithm. All 8 IHCS included
ICD-10 codes to identify a history of cancer. HFHS, KPCO,
KPGA, KPHI, KPNW, and University of Chicago included tumor
registry data. All 4 Kaiser Permanente systems and HFHS included
revenue codes, procedure codes, oncology department visits, and
chemotherapy in their final algorithm. Supplementary Table S1
describes the changes KPCO made to their initial algorithm, including the addition of ICD-10 codes Z86.0, Z86.00, and
Z86.000.

To calculate weighted sensitivity for HFHS, KPCO, KPGA,
KPHI, and KPNW (Figure 1), we assumed the tumor registry
sensitivity was 100% and the overall sensitivity was a weighted
average of the tumor registry sensitivity and the chart review sensitivity. Using Figure 1 described in the Materials and methods
section and the KPCO results, Table 3 provides an example of
how the weighted sensitivity was calculated. For example,
KPCO’s tumor registry’s sensitivity is 100% and includes 47.04%
of the total number of cancer cases identified. The KPCO calculated algorithm sensitivity for members not in the tumor registry
and based on chart review was 82.35% (sensitivity ¼14/17), and
the percentage of cancers not in the tumor registry was 52.96%.
The weighted sensitivity combines each of these percentages and
sensitivities to report a final weighted sensitivity of 90.65%
(weighted sensitivity ¼ (47.04%  100%) þ (52.96% 
82.35%)). Supplementary Table S2 provides a more detail on the
weighted sensitivities from HFHS, KPCO, KPGA, KPHI, and
KPNW.
Table 4 reports the performance metrics of the final algorithm
by IHCS. The algorithm’s sensitivity, or the ability to detect true
cancer cases, remained above 90% across all IHCS (HP ¼ 100%;
HFHS ¼ 97.66%; KPCO ¼ 90.65%; KPGA ¼ 100%; KPHI ¼ 100%;
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HealthPartners Henry Ford Kaiser Perma- Kaiser Perma- Kaiser Perma- Kaiser Perma- University Sanford
Institute
Health System nente Colorado nente Georgia nente Hawaii nente Northwest of Chicago Health

12465

100%
7223
57.95%
94.44%
17

18

42.05%
97.66%
79

82

96.3%

NA

NA
NA
NA
100%
5

5

NA
NA
40

45

88.89%

Henry Ford Health
System

92.77%

83

77

90.65%

52.96%

17

14

82.35%

47.04%

100%
5650

12012

89.89%

89

80

100%

51.69%

11

11

100%

48.31%

100%
3331

6895

87.91%

91

80

100%

35.74%

9

9

100%

64.26%

100%
3312

5154

90.80%

87

79

100%

38.66%

12

12

100%

61.34%

100%
8846

14421

Kaiser Permanente Kaiser Permanente Kaiser Permanente Kaiser Permanente
Colorado
Georgia
Hawaii
Northwest

97.9%

96

94

NA

NA

14

13

92.9%

NA

NA
NA

NA

University
of Chicago

b
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96.8%

188

182

NA

NA

187

184

98.4%

NA

NA
NA

NA

Sanford
Health

HealthPartners Institute developed an algorithm with a high sensitivity that leverages electronic medical record system to identify cancer adults who are not eligible to participate in Connect for Cancer Prevention.
HealthPartners Institute, University of Chicago, and Sanford Health based their algorithm’s sensitivity and specificity on chart abstraction and did not include the sensitivity of their tumor registry.
c
Henry Ford Health System and the Kaiser Permanente (KP) sites calculated a weighted sensitivity to account for the algorithm and tumor registry’s sensitivity within the Henry Ford Health System and KP EMR data.

a

Number of cancer cases in the eligible population identified in tumor
registry or by algorithm
Sensitivity Tumor registry sensitivityb,c
Number of cancer cases in tumor
registry
Percent of cancer cases that were
in the tumor registry
Calculated sensitivity for members
not in the tumor registry:
Number of patients in random
sample identified as cancer cases
by algorithm and chart review,
numerator
Number of patients in random
sample that were identified to
have cancer by chart review, denominator
Percent of cancer cases identified
by the algorithmb
Weighted average of the sensitivitiesb,c
Specificity Number of patients in random sample identified as cancer-free by algorithm and chart review,
numerator
Number of patients in random sample that were identified as cancerfree by chart review, denominator
Calculated Specificity

HealthPartners
Institutea

Table 4. Final algorithm performance based on randomized chart review across each integrated healthcare system
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KPNW ¼ 100%; University of Chicago ¼ 92.86%; and Sanford
Health ¼ 98.40%). Specificity was 87.91% or higher across all
IHCS.

A consortium of 8 IHCS partnered to develop and validate an algorithm to identify a patient’s history of cancer with high sensitivity
and specificity. Each site tailored the algorithm to their data systems
to achieve a sensitivity and specificity above 90% for both. False
negatives usually were a result of “history of cancer” being documented in the medical note or patient’s problem list, but with no
other supporting evidence in the EMR. False positives occurred infrequently and were usually a result of the algorithm identifying (1)
infusions or use of chemotherapies for conditions other than cancers
or (2) “cancer” diagnoses that were incorrectly reported by the patient, were benign lesions, or skin cancers that were documented in
notes or the problem list. For example, a patient reported a benign
lesion (such as a polyp) as a cancer, or documented a skin cancer
that was not reportable, such as basal cell cancer. The common
attributes of the final algorithm at each site were diagnosis codes.
Despite differences in EMR database systems, our method was robust and required only minor modifications to adapt to other IHCS.
The algorithm development is part of Connect for Cancer Prevention Study, a longitudinal cohort study planned to include 200
000 cancer-free adults to better understand cancer etiology and cancer outcomes (https://www.cancer.gov/connect-prevention-study/).
The developed algorithm will be applied to each enrolling IHCS as
part of the eligibility criteria used for participant recruitment. While
the algorithm’s sensitivity and specificity remained above 90%, we
acknowledge the algorithm may need to be revised throughout the
duration of the project to maintain an acceptable level of performance.
Local tumor registries can be utilized to identify incident cancer
cases but may miss individuals with a history of cancer that may
have been diagnosed prior to enrolling with a health plan. Furthermore, available tumor registry data can lag up to 2 years to account
for newly diagnosed cases and new information received about previously submitted cases. EMR databases contain information on the
most recent patient encounters and details on prior diagnoses and
diagnostic testing. Prior work by Clarke and Feigelson19 showed
that applying an algorithm within the EMR databases to identify
individuals with a distant or recent history of cancer can account for
these limitations and provide a suitable workaround. However, that
previous algorithm was only tested in a single IHCS and did not account for nuances between tumor registries and IHCS EMR data.
Our intent was to develop an algorithm to leverage the tumor
registry’s completeness of incident cancer cases and update diagnosis, treatment, and procedure codes that leverage the robust retrospective data in the EMR across several IHCS. By leveraging these
data, we can also account for history of cancer that is reported by
new members and patients to the IHCS as they continue to interact
with their healthcare providers. Had we relied solely on data from
each of the IHCS’ tumor registries and not included the EMR data,
we would have missed nearly half of the reported cancers. In addition to the algorithm being comprehensive of tumor registry and
EMR data, we aimed for the algorithm to be accessible across IHCS
and to accurately identify adults who did not have a history of cancer. Therefore, to improve the utility of the algorithm across IHCS,
we used only discrete data elements. By prioritizing utilization, coupled with high performance, the algorithm could be used for patient

surveillance in addition to identifying a cancer-free cohort for the
Connect for Cancer Prevention project.
As noted earlier, most invasive cancer diagnoses are included in
tumor registries that follow NAACCR standards, while reporting of
in situ cases is not as consistent. Therefore, it is important to distinguish in situ cases as they are represented in ICD-O-3 behavior codes
when applying the algorithm to an EMR database.26 For all tumors
diagnosed on or after January 1, 2001, NAACCR requires tumor
registries to include all cancers with an ICD-O-3 behavior code of 2
or 3 (in situ or malignant), with the exception of several skin carcinomas, and cervical and prostatic neoplasia.26
To our knowledge, our project is the first to partner with multiple IHCS to systematically develop an algorithm that will identify
individuals with a history of cancer, regardless of when that diagnosis occurred. However, there are limitations to our approach that
should be noted. First, the algorithm was developed and validated
across Epic-based EMRs and may not be easily applied to other
EMR databases. Second, our eligible cohort used to develop and validate the algorithm was restricted to individuals 40–65 years of age;
the algorithm may perform differently in a broader age group.
Third, each participating IHCS had a robust EMR system that dates
back between 15 and 25 years and the accuracy of the algorithm is
limited by the completeness of the EMR. Applying the algorithm to
an EMR system that is less complete or does not include historic information will decrease the accuracy as there will be less cases for
the algorithm to sample. Fourth, the algorithm did not include data
elements such as medical notes or prescription drugs which may
have improved the sensitivity but decreased the specificity or the
ability to implement across IHCS. Future algorithm revisions should
consider adding these elements and assess the algorithm for accuracy. Finally, data may be missing for IHCS members who are relatively new to the health plan, or who rarely interact with the
healthcare system.

CONCLUSION
We developed and validated a high-performing algorithm to identify
individuals with a history of cancer as part of eligibility criteria for a
prospective cohort study of cancer-free adults. Combining the
strengths of tumor registries and EMR creates a robust algorithm
that can identify those with a history of cancer, regardless of
whether that diagnosis was recent or in the distant past. The ability
to identify this broad group may be beneficial for quality improvement projects that outreach to individuals with a history of cancer,
specifically to newly enrolled members and new patients of a health
plan to identify unmet or ongoing healthcare needs. The algorithm
could be applied to other healthcare systems that employ an EMR
and have tumor registry data available, or to supplement the tumor
registry to identify incident cancer cases diagnosed within 0–12
months and may not yet be included in the registry.
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